Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 2/20 | 0.42 |
| ▸ | PTGES | O14684 | 6/20 | 0.37 |
| ▸ | FAAH | O00519 | 3/20 | 0.35 |
| ▸ | WDR5 | P61964 | 4/20 | 0.35 |
| ▸ | ACACA | Q13085 | 4/20 | 0.34 |
| ▸ | ACACB | O00763 | 2/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17634884 | 0.91 | PRKDC (0.44) | PRKDCPTGESFAAH | |
| SCHEMBL17634852 | 0.90 | PRKDC (0.44) | PRKDCFAAH | |
| SCHEMBL15339669 | 0.88 | PRKDC (0.45) | PRKDCFAAH | |
| SCHEMBL17634845 | 0.87 | PRKDC (0.48) | PRKDCPTGESFAAHWDR5ACACA | |
| SCHEMBL15339658 | 0.87 | PRKDC (0.44) | PRKDCFAAH | |
| SCHEMBL17634873 | 0.87 | PRKDC (0.44) | PRKDCFAAH | |
| SCHEMBL17634851 | 0.86 | PRKDC (0.46) | PRKDCFAAH | |
| SCHEMBL15339627 | 0.86 | PRKDC (0.47) | PRKDCFAAH | |
| SCHEMBL22838686 | 0.85 | PTGES (0.36) | PTGESWDR5ACACAACACBSYK | |
| SCHEMBL17874690 | 0.85 | PRKDC (0.48) | PRKDCFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021465-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-06-01 | — | — | US | disclosed |
| US-11008305-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-05-18 | — | — | US | disclosed |
| US-10442791-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-10-15 | — | — | US | disclosed |
| US-10391095-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-08-27 | — | — | US | disclosed |
| US-20180193341-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2018-07-12 | — | — | US | disclosed |
| US-9925188-B2 | DNA-PK inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-03-27 | — | — | US | disclosed |
| US-9925188-B2 | DNA-PK inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-03-27 | — | — | US | disclosed |
| EP-3057959-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2018-02-28 | — | — | EP | disclosed |
| US-9878993-B2 | DNA-PK inhibitors for treatment of cancer | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-01-30 | — | — | US | disclosed |
| US-9878993-B2 | DNA-PK inhibitors for treatment of cancer | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-01-30 | — | — | US | disclosed |
| US-9592232-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-03-14 | — | — | US | disclosed |
| US-9592232-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-03-14 | — | — | US | disclosed |
| US-9376448-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-06-28 | — | — | US | disclosed |
| US-9376448-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-06-28 | — | — | US | disclosed |
| US-9296701-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296701-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008305-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | PRKDC 33/4885PTGES 2286/4885FAAH 3955/4885 |
| US-10442791-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | PRKDC 33/4885PTGES 2286/4885FAAH 3955/4885 |
| US-20180193341-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | PRKDC 33/4885PTGES 2286/4885FAAH 3955/4885 |
| US-10391095-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | PRKDC 33/4885PTGES 2286/4885FAAH 3955/4885 |
| US-11021465-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | PRKDC 33/4885PTGES 2286/4885FAAH 3955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.